Rescuing DR4/5 agonists as a therapeutic class will require designing antibodies that can achieve values of k and τ that exceed θ in a large fraction of cancer cell types either individually or in combination with agents such as bortezomib; high-affinity binding to TRAIL receptors is not sufficient. The gene discussed is TNFRSF10A; the disease is cancer.